Perrigo Reports Record Sales, Earnings and Cash Flow From Operations for F...( Adjustment to adopt ...),Health

Date:8/18/2009

Adjustment to adopt FSP FAS 115-2 - - (5,000) (5,000) 5,000 Post-retirement liability adjustments, net of $214 tax - - (398) (398) - Issuance of common stock under: Stock options 720 10,062 - - - Restricted stock plan 14 - - - - Compensation for stock options - 3,313 - - - Compensation for restricted stock - 7,040 - - - Cash dividends, $0.215 per share - - - - (19,957) Tax effect from stock transactions - 5,780 - - - Purchases and retirements of common stock (1,836) (62,489) - - - ------ ------- ----- ----- ----- Balance at June 27, 2009 92,209 $452,243 $50,592 39,457 419,086 ====== ======== ======= ====== ======= PERRIGO COMPANY CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) Fiscal Year ----------- 2009 2008 2007 ---- ---- ---- Cash Flows From (For) Operating Activities Net income $144,049 $135,773 $73,797 Adjustments to derive cash flows Write-off of in- process research and development 279
'/>"/>

SOURCE Perrigo Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Related medicine news :

1. Perrigo Company Announces Quarterly Dividend
2. Perrigo Company Will Release Fiscal Year 2009 Results on August 18, 2009
3. Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
4. Perrigo Receives FDA Approval to Market Cherry and Cinnamon Flavored Nicotine Lozenges
5. Perrigo Confirms That its Partner Synthon Has Filed for Generic Version of Xyzal(R) Solution and Announcement of Lawsuit by Sepracor/UCB
6. Perrigo Reports Record Third Quarter
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
9. Perrigo Begins Shipments of Ibuprofen PM
10. Perrigo Reports Record Second Quarter Sales
11. Perrigo Company Announces Quarterly Dividend